Latest Tax Incentives News

Bluechiip Limited advances its strategic repositioning with a new licensing agreement valued up to USD 750,000 alongside ongoing efforts to lift its trading suspension and grow sales.

Terragen Holdings reports robust quarterly progress, highlighted by successful beef feedlot trials and a $4.76 million equity raise, setting the stage for its new probiotic product launch in March 2025.

Cycliq Group Ltd reports a robust Q2 FY2025 with a 15% rise in cash receipts to $1.92 million and strategic leadership appointments aimed at accelerating growth.

Identitii reports solid quarterly progress highlighted by a strategic new director appointment, US market expansion, and a successful $1.8 million capital raise, underpinning its path toward profitability.

FBR Limited has successfully completed its US Demonstration Program with CRH Ventures, raising $8 million through a Share Purchase Plan and positioning itself for a significant joint venture in the US construction robotics market.

Argenica Therapeutics has dosed 80% of patients in its Phase 2 stroke trial and gained FDA orphan drug designations for its second candidate, ARG-006. The company reports a cash-positive quarter with $15 million in reserves.

Tivan Limited has advanced its Speewah Fluorite Project with a $7.4 million government grant and Major Project Status, alongside a joint venture MoU with Sumitomo Corporation and promising drilling results at Sandover.

Cynata Therapeutics reports encouraging Phase 1 results for its diabetic foot ulcer treatment CYP-006TK, alongside a strengthened balance sheet and ongoing clinical progress.

Patrys Limited has halted plans for a Phase 1 trial of PAT-DX1 following disappointing GMP production results, pivoting its development efforts towards PAT-DX3 and exploring new partnerships.

Acrux Limited has launched its Nitroglycerin 0.4% Ointment and successfully raised nearly $4 million, positioning the specialty pharma company for sustained revenue growth.

Omega Oil and Gas Limited has successfully raised A$7 million in a strongly supported institutional placement, positioning the company to advance its Canyon-1H fracture stimulation and appraisal program.

Bio-Gene Technology Limited has advanced its bio-insecticide pipeline with two U.S. Department of Defense grants totaling A$3 million, alongside key regulatory and production milestones for Flavocide® and Qcide®.